5 results about "Glucan synthesis" patented technology

The application belongs to the technical field of biological gene engineering, and particularly relates to a barley HvCslf6 promoter element and application thereof in regulating the content of barley grain beta-glucan, wherein the barley HvCslf6 promoter element is located at 295bp-300bp upstream of a transcription start site of a barley HvCslf6 gene; the nucleotide sequence of the HvCslf6 promoter element is CCGTTG, and the HvCslf6 promoter element belongs to a CCAAT-box element; the gene number of the HvCslf6 gene in BARLEX Morex v3 Gene Models is HORVU.MOREX.r3.7HG0698110. The application finds a key element which can affect the content of beta-glucan in barley grains in the upstream promoter region of a main effect gene HvCslf6 of barley beta-glucan synthesis by using a gene editing technology, and thus provides a method capable of preparing transgenic plants with changed content of beta-glucan in barley grains, and provides a new means and tool for detecting and regulating the content of beta-glucan in barley grains.

This invention belongs to the field of microbial fermentation technology and discloses a method and application for improving the production of staminodesmotic acid (Sclerotium sclerotiorum) based on dynamic osmotic pressure regulation. The method uses *Sclerotium sclerotiorum* as the production strain and employs a synergistic strategy of initial culture medium component optimization, precise osmotic pressure regulation during fermentation, and dynamic feeding to enhance synthesis. Utilizing the dual characteristics of sucrose as a carbon source and osmotic pressure regulator, and the osmotic pressure regulating effect of KCl, the osmotic pressure during fermentation is precisely controlled between 1050-1300 mOsmol / kg. This activates the MAPK-CWI signaling pathway and FKs2 gene expression, directionally promoting staminodesmotic acid synthesis and increasing staminodesmotic acid yield. This invention, by optimizing the initial carbon source and inorganic salt concentration, precisely regulating osmotic pressure during fermentation through feeding, and combining molecular mechanism analysis, achieves a significant increase in staminodesmotic acid yield, reduces industrial production costs, and provides technical support for the large-scale industrial production of staminodesmotic acid.

This application relates to the field of biotechnology, specifically disclosing a *Pichia pastoris* yeast, its construction method, and its applications. This application involves knocking out the *gas1* gene, which is related to β-glucan synthesis, in *Pichia pastoris*. By deleting the *gas1* gene, which encodes β-glucan in the cell wall of *Pichia pastoris*, this application reduces cell size, decreases the transfer distance from the cell surface to the nucleus, improves oxygen transfer and product secretion during high-density culture, and enhances fermentation efficiency. Furthermore, the *Pichia pastoris* yeast constructed using this application enhances the synthesis of the intracellular product bisabolol and also enhances its secretion capacity. This application, by reducing cell size and decreasing the carbon flow to cell wall polysaccharide synthesis while increasing the carbon source flow to target product synthesis, has significant implications for industrial production.

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

The present application relates to the technical field of biological medicine, in particular to an antifungal drug composition based on (1,3)-beta-D-glucan synthase inhibitor and application thereof. In vivo and in vitro experiments prove that the combination of endogenous antibacterial peptide LL-37 and (1,3)-beta-D-glucan synthase inhibitor (such as caspofungin, micafungin, anidulafungin, rezafungin and albaconazole) shows significant synergistic inhibitory effect on multiple drug-resistant pathogenic fungi such as Candida albicans and Candida auris. Since free antibacterial peptides are easily degraded by proteases, the present application is based on the synergistic killing mechanism of breaking the network barrier of fungal cell wall and assisting endogenous defense peptide to target cell membrane, and ingeniously uses the "antibacterial peptide LL-37 expression promoter" to actively up-regulate the synthesis of host natural peptides, which provides a new drug regimen for clinical treatment of deep fungal infection.